AKS-452

N/A

Report date: 2022/03/18 11:23:06

Base Information

Drug NameAKS-452
Drug Alias NameSARS-CoV-2-RBD-Fc fusion proteinAKS-452
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAkston Biosciences Corp
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Medical Center GroningenBiolexis PteAkston Biosciences Corp
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A